When older adolescents miss part of their MenABCWY vaccination series, they remain vulnerable 1,2

Teens are at increased risk of infection from all 5 leading meningococcal serogroups 3,4

Risk posed by all
5

leadingserogroups

(A, B, C, W, and Y) rises between the ages of 15 and 22 . 4*

older adolescents walking across the schoolyard together

Actor portrayal.

>

85

%

of meningococcal disease cases in the US are caused by serogroups A, B, C, W, and Y. 3*

*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults. 3
older adolescents huddled together during a sports game

Actor portrayal.

*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults. 3
*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults. 3

CDC’s ACIP recommends MenABCWY coverage for all eligible healthy teens2†‡

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with a MenACWY vaccine for all adolescents, with the first dose at age 11 or 12 years and a booster dose at age 16. Adolescents who receive the first dose at age 13 to 15 years should receive a booster dose at age 16 to 18 years, with a minimum interval of 8 weeks between doses. Adolescents who receive their first dose of MenACWY vaccine at or after age 16 years do not need a booster dose.

ACIP also recommends adolescents age 16 to 23 years (preferred age 16 to 18 years) receive 2 doses of a MenB vaccine for short-term protection against most strains of serogroup B meningococcal disease based on shared clinical decision-making.

†For further guidance on individuals in older age groups or at increased risk, please click the button.

Most healthcare professionals, like you, recommend vaccinating eligible teens against all 5 leading meningococcal serogroups5‡
most healthcare professionals believe vaccinating eligible teens against the 5 leading meningococcal serogroups is vitalmost healthcare professionals believe vaccinating eligible teens against the 5 leading meningococcal serogroups is vital
In a recent survey of HCPs (n=500):
95.6%
of HCPs highly recommend all of their teen patients get all recommended meningococcal vaccines (ACWY and B) and required doses to help protect against all 5 leading serogroups.5
75.2%
of HCPs agree that most parents incorrectly believe their teen is fully protected against all 5 leading serogroups.5
98.6%
of HCPs agree a combined MenABCWY vaccine that covers all 5 leading serogroups can help close gaps in protection and increase vaccination rates in teens.5
syringe icon for vaccination against the 5 most common meningococcal serogroups
Closing gaps in meningococcal vaccination starts with you—vaccinate your eligible older adolescent patients against all 5 leading meningococcal serogroups.3,6‡
icon for gaps in vaccine coverage against the 5 leading serogroups leaves many teens at risk for meningococcal disease

Gaps in Coverage

Gaps in coverage against all 5 leading serogroups leave most older adolescents at risk3,6

See More

icon for learning about a meningococcal vaccine

A New Option

Learn about a new vaccine that could help you close gaps in coverage7

Discover

‡ACIP recommends routine administration of a MenACWY vaccine for all healthy persons aged 11 to 18 years, with a single dose at age 11 or 12, followed by a booster dose at age 16. ACIP also recommends a 2-dose MenB vaccine series administered 1 to 6 months apart for healthy persons aged 16 to 23 years on the basis of shared clinical decision-making, with a preferred age range of 16 to 18. For further guidance on individuals in older age groups or at increased risk, see ACIP Meningococcal Vaccine Recommendations.2

CDC=Centers for Disease Control and Prevention; HCP=healthcare professional.

References

  1. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed October 12, 2021. Accessed August 2, 2023. https://www.cdc.gov/vaccines/vpd/mening/index.html

  2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.

  3. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.

  4. Meningococcal disease: surveillance data tables. Centers for Disease Control and Prevention. Last reviewed July 10, 2023. Accessed September 11, 2023. https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html

  5. Data on file. Pfizer; 2023.

  6. ‌Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912-919.

  7. Kroger A, Bahta L, Long S, Sanchez P. Vaccine recommendations and guidelines of the ACIP: general best practice guidelines for immunization. Centers for Disease Control and Prevention. Accessed August 31, 2023. https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/downloads/general-recs.pdf